{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117755","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.724169+00:00","generated_at":"2026-06-21T19:54:26.672648+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cognition Therapeutics reports Q3 net loss $6.6M; announces public offering of 5M shares at $1.20","bullets":["Public offering of 5,000,000 shares at $1.20/share; gross proceeds $6.0M; net ~$5.4M; underwriter option for 750k additional shares.","Q3 2022 net loss $6.6M ($0.29 diluted) vs $4.9M ($8.12) in Q3 2021; R&D expense $8.3M, G&A $4.4M.","Cash $46.6M at Sept 30; $93.6M in awarded grants remain available; cash runway extended into first half 2024.","Lead candidate CT1812 in three Phase 2 trials: SHINE expands to Europe, SEQUEL gets additional NIA grant, SHIMMER sites activating."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117755","json":"https://secwatch.observer/filing/0001104659-22-117755.json","markdown":"https://secwatch.observer/filing/0001104659-22-117755.md","text":"https://secwatch.observer/filing/0001104659-22-117755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/0001104659-22-117755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/tm2230367d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:54:26.672648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbea6e87cec8c139673953948677af9d7ffb980e","claim":"COGNITION THERAPEUTICS INC reported third quarter ended September 30, 2022 results: net income $6.6 million, EPS $0.29 per share.","evidence_excerpt":"Net loss attributable to common stockholders for the third quarter ended September 30, 2022, was $6.6 million or $0.29 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/0001104659-22-117755-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$6.6 million"},{"label":"EPS","value":"$0.29 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e82e4e9cd46d404811774182b2d1fc296f6ca886","claim":"COGNITION THERAPEUTICS INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at 5,000,000 shares of common stock at $1.20 per share (effective 2022-11-10).","evidence_excerpt":"On November 10, 2022, Cognition Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co., as representative of the several underwriters named in Schedule A thereto (the “Underwriters”), relating to the public offering (the “Offering”) of 5,000,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), at a price to the public of $1.20 per share (the “Offering Price”), less underwriting discounts and commissions.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465922117755/0001104659-22-117755-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"5,000,000 shares of common stock at $1.20 per share"},{"label":"Effective","value":"2022-11-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}